Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody

Background and objectives Glofitamab, tafasitamab, loncastuximab tesirine, polatuzumab, and selinexor have been proposed for the treatment of relapsed-refractory diffuse large B-cell lymphoma (DLBCL). We studied the pattern of overall survival (OS) for these five agents. Methods We reconstructed pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Messori, Andrea, Rivano, Melania, Mengato, Daniele, Chiumente, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886407/
https://www.ncbi.nlm.nih.gov/pubmed/36726938
http://dx.doi.org/10.7759/cureus.33169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886407/
https://www.ncbi.nlm.nih.gov/pubmed/36726938
http://dx.doi.org/10.7759/cureus.33169

Ejemplares similares